Trevi Therapeutics (TRVI) News Today $2.95 -0.15 (-4.84%) (As of 09/6/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 Time Period September 7 at 7:12 AM | yahoo.comCity of Rome says it is planning to limit numbers of tourists at the Trevi Fountain as it struggles with overtourismSeptember 6 at 9:08 PM | apnews.comRome could start charging tourists to visit the Trevi FountainSeptember 6 at 4:08 PM | cnn.comRome may limit tourist access to Trevi FountainSeptember 6 at 4:08 PM | apnews.comA wish at Rome’s Trevi Fountain could soon cost more than the coin you tossSeptember 6 at 9:32 AM | insidertrades.comInsider Selling: Trevi Therapeutics, Inc. (NASDAQ:TRVI) CEO Sells 10,981 Shares of StockSeptember 6 at 7:30 AM | marketbeat.comWhy Trevi Therapeutics Could Be a Triple-Bagger Biotech StockWall Street analysts see big potential upside for small-cap biopharma firm Trevi Therapeutics. So, what does the firm do and how does it stand out?September 6 at 2:01 AM | washingtonpost.comRome floats plan to charge tourists at Trevi FountainSeptember 5 at 6:55 PM | marketbeat.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) CEO Sells $33,162.62 in StockTrevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) CEO Jennifer L. Good sold 10,981 shares of the stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $3.02, for a total transaction of $33,162.62. Following the completion of the sale, the chief executive officer now owns 213,313 shares of the company's stock, valued at approximately $644,205.26. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.September 5 at 3:58 PM | skift.comRome Eyes Tourist Reservation System for Trevi FountainSeptember 5 at 10:58 AM | reuters.comRome considering limiting tourist access to Trevi FountainSeptember 4 at 4:05 PM | prnewswire.comTrevi Therapeutics Announces Oral Presentation on Data from Ph2a CANAL Trial at the European Respiratory Society Congress 2024September 2, 2024 | americanbankingnews.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Receives $7.80 Average Target Price from AnalystsSeptember 1, 2024 | msn.comHC Wainwright & Co. Initiates Coverage of Trevi Therapeutics (TRVI) with Buy RecommendationSeptember 1, 2024 | msn.comRaymond James Initiates Coverage of Trevi Therapeutics (TRVI) with Outperform RecommendationAugust 31, 2024 | americanbankingnews.comTrevi Therapeutics (NASDAQ:TRVI) Now Covered by Analysts at HC WainwrightAugust 31, 2024 | americanbankingnews.comTrevi Therapeutics (NASDAQ:TRVI) Now Covered by Analysts at Raymond JamesAugust 30, 2024 | finance.yahoo.comAbercrombie upgraded, Dollar General downgraded: Wall Street's top analyst callsAugust 30, 2024 | insidertrades.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Director Sells $13,346.15 in StockAugust 30, 2024 | marketbeat.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Average Recommendation of "Buy" from AnalystsTrevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) has earned an average rating of "Buy" from the six research firms that are covering the firm, Marketbeat.com reports. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The avAugust 30, 2024 | marketbeat.comTrevi Therapeutics (NASDAQ:TRVI) Coverage Initiated at Raymond JamesRaymond James assumed coverage on Trevi Therapeutics in a research note on Friday. They set an "outperform" rating and a $9.00 price target for the company.August 29, 2024 | marketbeat.comInsider Selling: Trevi Therapeutics, Inc. (NASDAQ:TRVI) Director Sells 4,555 Shares of StockTrevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) Director David P. Meeker sold 4,555 shares of the business's stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $2.93, for a total value of $13,346.15. Following the completion of the sale, the director now directly owns 352,489 shares in the company, valued at $1,032,792.77. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.August 28, 2024 | prnewswire.comTrevi Therapeutics to Participate in September Investor and Medical ConferencesAugust 20, 2024 | marketbeat.comEF Hutton Acquisition Co. I Upgrades Trevi Therapeutics (NASDAQ:TRVI) to Strong-BuyEF Hutton Acquisition Co. I upgraded Trevi Therapeutics to a "strong-buy" rating in a research report on Monday.August 18, 2024 | mirror.co.ukWhat happens to tossed into Rome's Trevi Fountain as real answer may surprise youAugust 18, 2024 | finance.yahoo.comTRVI Sep 2024 5.000 call (TRVI240920C00005000)August 17, 2024 | insidertrades.comThomas Sciascia Sells 18,660 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) StockAugust 16, 2024 | marketbeat.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Insider Thomas Sciascia Sells 18,660 SharesTrevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) insider Thomas Sciascia sold 18,660 shares of the business's stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $2.76, for a total transaction of $51,501.60. Following the sale, the insider now owns 220,315 shares of the company's stock, valued at approximately $608,069.40. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.August 15, 2024 | markets.businessinsider.comOppenheimer Keeps Their Buy Rating on Trevi Therapeutics (TRVI)August 15, 2024 | marketbeat.comB. Riley Research Analysts Decrease Earnings Estimates for Trevi Therapeutics, Inc. (NASDAQ:TRVI)Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) - Research analysts at B. Riley dropped their Q3 2024 EPS estimates for Trevi Therapeutics in a report issued on Tuesday, August 13th. B. Riley analyst M. Mamtani now forecasts that the company will post earnings of ($0.09) per share for the quAugust 14, 2024 | finance.yahoo.comTrevi Therapeutics, Inc. (TRVI)August 10, 2024 | markets.businessinsider.comImpending Catalysts and Financial Stability Bolster Buy Rating for Trevi TherapeuticsAugust 8, 2024 | investorplace.comTRVI Stock Earnings: Trevi Therapeutics Misses EPS for Q2 2024August 8, 2024 | prnewswire.comTrevi Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates Reaffirming Clinical Trial GuidanceAugust 2, 2024 | msn.comThe Trevi Fountain Incident – This Tourist Took It Too FarAugust 2, 2024 | marketbeat.comTrevi Therapeutics (TRVI) to Release Earnings on ThursdayTrevi Therapeutics (NASDAQ:TRVI) will be releasing earnings after the market closes on Thursday, August 8, Zacks reports.August 1, 2024 | prnewswire.comTrevi Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on August 8, 2024July 29, 2024 | markets.businessinsider.comAnalysts’ Top Healthcare Picks: Trevi Therapeutics (TRVI), Quanterix (QTRX)July 27, 2024 | marketbeat.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Sees Significant Increase in Short InterestTrevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) was the target of a significant increase in short interest in the month of July. As of July 15th, there was short interest totalling 1,270,000 shares, an increase of 32.6% from the June 30th total of 957,600 shares. Based on an average daily trading volume, of 225,000 shares, the days-to-cover ratio is currently 5.6 days.July 23, 2024 | msn.comWhat happens to all the money thrown in Rome's Trevi Fountain?July 2, 2024 | prnewswire.comTrevi Therapeutics to Participate in Upcoming Investor and Healthcare EventsJune 15, 2024 | marketbeat.comOpaleye Management Inc. Boosts Stock Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI)Opaleye Management Inc. lifted its position in Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 48.6% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,535,000 shares of the company's stock after buyiJune 13, 2024 | marketbeat.comFrazier Life Sciences Management L.P. Boosts Stake in Trevi Therapeutics, Inc. (NASDAQ:TRVI)Frazier Life Sciences Management L.P. raised its position in Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 7.3% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 7,381,090 shares of the company's stock after buying an additional 500,00June 1, 2024 | insidertrades.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Insider Sells $136,088.40 in StockMay 25, 2024 | insidertrades.comInsider Selling: Trevi Therapeutics, Inc. (NASDAQ:TRVI) CFO Sells 4,350 Shares of StockMay 23, 2024 | insidertrades.comInsider Selling: Trevi Therapeutics, Inc. (NASDAQ:TRVI) CEO Sells 25,037 Shares of StockMay 22, 2024 | marketbeat.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) CEO Sells $71,605.82 in StockTrevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) CEO Jennifer L. Good sold 25,037 shares of the stock in a transaction that occurred on Monday, May 20th. The stock was sold at an average price of $2.86, for a total value of $71,605.82. Following the completion of the sale, the chief executive officer now owns 213,313 shares of the company's stock, valued at approximately $610,075.18. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.May 15, 2024 | insidertrades.comInsider Selling: Trevi Therapeutics, Inc. (NASDAQ:TRVI) CEO Sells 4,578 Shares of StockMay 14, 2024 | marketbeat.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) CEO Sells $13,276.20 in StockTrevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) CEO Jennifer L. Good sold 4,578 shares of the company's stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $2.90, for a total value of $13,276.20. Following the transaction, the chief executive officer now directly owns 213,313 shares of the company's stock, valued at $618,607.70. The transaction was disclosed in a filing with the SEC, which is accessible through this link.May 13, 2024 | seekingalpha.comTrevi Therapeutics, Inc. (TRVI) Q1 2024 Earnings Call TranscriptMay 13, 2024 | finance.yahoo.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Q1 2024 Earnings Call Transcript Get Trevi Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TRVI and its competitors with MarketBeat's FREE daily newsletter. Email Address Fmr CIA Advisor reveals PEACEMAKER superweapon (Ad)Kamala cannot get the “codes” to this superweapon. In Trump’s hands, it will restore America’s global dominance. It could also help Americans struggling under Bidenomics by potentially sending 5 military stocks SOARING. Historically, similar stocks have shot up 16,270% in just 18 months. Full details are in this announcement. TRVI Media Mentions By Week TRVI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TRVI News Sentiment▼0.170.55▲Average Medical News Sentiment TRVI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TRVI Articles This Week▼152▲TRVI Articles Average Week Get Trevi Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TRVI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: VNDA News VYNE News CARA News TECX News CRON News IMNM News ZYME News CRGX News DNTH News PAHC News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TRVI) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trevi Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Trevi Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.